Piper Sandler lowers aTyr Pharma stock price target on valuation
Piper Sandler cut aTyr Pharma's (ATYR) price target to $35 from $280, keeping an Overweight rating. The biotech firm's stock trades at $6.03, down over 80% in a year. The firm adjusted its target after aTyr's Q3 2026 earnings report, which included Phase 3 trial updates for efzofitimod. aTyr ended Q3 2026 with $50.3M in cash. The company announced a 1-for-40 reverse stock split, effective October 28.
How this was made
The 30-second read
Why it matters
Analyst target reduction reflects skepticism on trial outcomes and valuation, likely prompting short‑term sell pressure.
Market read
The price‑target cut is a fresh, material analyst action for ATYR, a stock already under pressure, and may trigger further downside.
What to watch
Cash runway of $50M may support continued trial funding, mitigating downside risk.
Background
ATYR is a micro‑cap biotech with a Phase 3 trial in pulmonary sarcoidosis; its stock has fallen sharply over the past year.
Ticker impact
Piper Sandler cut ATYR's price target to $35 from $280 after its Q3 2026 earnings and Phase 3 trial update.
downward pressure as investors price in the reduced target
Analyst downgrade with a 87% target reduction is a strong bearish signal for a micro‑cap biotech.
Market effects
May weigh on other small‑cap biotech stocks awaiting trial data.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The reverse split could improve liquidity and attract new investors despite the target cut.
Key entities
- AnalystPiper Sandler
Equity research firm that lowered ATYR's price target.
- CompanyaTyr Pharma
Biotech developing efzofitimod for pulmonary sarcoidosis.
